36.24
+4.24(+13.25%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
2578
First IPO Date
December 24, 2018
| Name | Title | Pay | Year Born |
| Mr. Cong Li | Co-Chief Executive Officer & Executive Director | 0 | 1964 |
| Dr. Jianjun Zou M.D., Ph.D. | GM, Chief Executive Officer & Executive Director | 0 | 1971 |
| Dr. Sheng Yao Ph.D. | Deputy GM, Senior Vice President & Executive Director | 0 | 1975 |
| Mr. Baohong Xu | Chief Financial Officer | 0 | 1979 |
| Dr. Ning Li M.D., Ph.D. | Executive Vice-Chairman of the Board | 0 | 1961 |
| Dr. Gang Wang | Deputy GM, Chief Quality Officer, Senior Vice President of Industry Affairs & Executive Director | 0 | 1957 |
| Mr. Zhuobing Zhang | Deputy GM & Executive Director | 0 | 1967 |
| Dr. Xin Li | Senior Vice President of Government Affairs & Executive Director | 0 | 1979 |
| Mr. Jun Xiong | Executive Chairman | 0 | 1974 |
| Mr. Zhengyu Wang | Joint Company Secretary | 0 | 1995 |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.